These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 26768619)
1. DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models. Wang W; Wang H; Ni Y; Yao Z; Ye L; Tian J Tumour Biol; 2016 Jul; 37(7):9221-32. PubMed ID: 26768619 [TBL] [Abstract][Full Text] [Related]
2. NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis. Yu P; Ye L; Wang H; Du G; Zhang J; Zuo Y; Zhang J; Tian J PLoS One; 2014; 9(12):e115041. PubMed ID: 25551444 [TBL] [Abstract][Full Text] [Related]
3. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer. Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694 [TBL] [Abstract][Full Text] [Related]
4. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling. Wang H; Zhang C; Ning Z; Xu L; Zhu X; Meng Z Int J Oncol; 2016 Mar; 48(3):1229-41. PubMed ID: 26782953 [TBL] [Abstract][Full Text] [Related]
5. NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Yu P; Ye L; Wang H; Du G; Zhang J; Zhang J; Tian J Tumour Biol; 2015 Mar; 36(3):2143-53. PubMed ID: 25398692 [TBL] [Abstract][Full Text] [Related]
6. The novel VEGF receptor 2 inhibitor YLL545 inhibits angiogenesis and growth in breast cancer. Zhang J; Liu C; Shi W; Yang L; Zhang Q; Cui J; Fang Y; Li Y; Ren G; Yang S; Xiang R Oncotarget; 2016 Jul; 7(27):41067-41080. PubMed ID: 27203384 [TBL] [Abstract][Full Text] [Related]
7. Salinomycin exerts anti-angiogenic and anti-tumorigenic activities by inhibiting vascular endothelial growth factor receptor 2-mediated angiogenesis. Li T; Liu X; Shen Q; Yang W; Huo Z; Liu Q; Jiao H; Chen J Oncotarget; 2016 May; 7(18):26580-92. PubMed ID: 27058891 [TBL] [Abstract][Full Text] [Related]
8. Oleanolic Acid Inhibits Colorectal Cancer Angiogenesis by Blocking the VEGFR2 Signaling Pathway. Niu G; Sun L; Pei Y; Wang D Anticancer Agents Med Chem; 2018; 18(4):583-590. PubMed ID: 29065844 [TBL] [Abstract][Full Text] [Related]
9. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720 [TBL] [Abstract][Full Text] [Related]
10. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
11. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways. Li X; Wang X; Ye H; Peng A; Chen L Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678 [TBL] [Abstract][Full Text] [Related]
12. Norcantharidin: a potential antiangiogenic agent for gallbladder cancers in vitro and in vivo. Zhang JT; Fan YZ; Chen CQ; Zhao ZM; Sun W Int J Oncol; 2012 May; 40(5):1501-14. PubMed ID: 22200632 [TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. Huynh H; Ong R; Zopf D J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182 [TBL] [Abstract][Full Text] [Related]
14. 1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases. Lu YY; Wang JJ; Zhang XK; Li WB; Guo XL J Pharm Pharmacol; 2015 Oct; 67(10):1393-405. PubMed ID: 26076716 [TBL] [Abstract][Full Text] [Related]
15. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis. Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414 [TBL] [Abstract][Full Text] [Related]
16. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways. Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330 [TBL] [Abstract][Full Text] [Related]
17. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo. Zhang L; Kim S; Ding W; Tong Y; Zhang X; Pan M; Chen S Drug Des Devel Ther; 2015; 9():5579-90. PubMed ID: 26487802 [TBL] [Abstract][Full Text] [Related]
18. SKLB-M8 induces apoptosis through the AKT/mTOR signaling pathway in melanoma models and inhibits angiogenesis with decrease of ERK1/2 phosphorylation. Wang J; Yang Z; Wen J; Ma F; Wang F; Yu K; Tang M; Wu W; Dong Y; Cheng X; Nie C; Chen L J Pharmacol Sci; 2014; 126(3):198-207. PubMed ID: 25341684 [TBL] [Abstract][Full Text] [Related]
19. YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models. Xia Y; Song X; Li D; Ye T; Xu Y; Lin H; Meng N; Li G; Deng S; Zhang S; Liu L; Zhu Y; Zeng J; Lei Q; Pan Y; Wei Y; Zhao Y; Yu L Sci Rep; 2014 Aug; 4():6031. PubMed ID: 25112436 [TBL] [Abstract][Full Text] [Related]
20. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. Tao C; Lin H; Chen S Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]